臨床外科79巻7号

2024年07月発行

特集 外科医が知っておくべき 肝胆膵腫瘍に対する薬物療法 肝臓

転移性肝癌に対する周術期化学療法

著者： 風見由祐¹ 河口義邦¹ 長谷川潔¹

所属機関： ¹東京大学医学部附属病院肝胆膵外科・人工臓器移植外科

ページ範囲：P.736 - P.743

【ポイント】
◆転移性肝癌のなかで大腸癌肝転移は外科治療の有効性が確立されており，周術期化学療法が一般的に行われている．
◆大腸癌肝転移は腫瘍条件により“切除可能”と“切除不能”に大別され，それぞれで周術期化学療法の担う役割が異なる．
◆切除可能大腸癌肝転移では肝切除を治療の軸にして，術前/術後補助化学療法をどのように組み入れるかが課題となっている．
◆切除不能大腸癌肝転移は化学療法を導入した後，conversion surgeryを行えるかが治療の鍵であり，どの化学療法をどれくらいの期間行うかが重要な問題である．

参考文献

1）Yamamoto M, Yoshida M, Furuse J, et al：Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021. J Hepatobiliary Pancreat Sci 28：1-25, 2021

2）Pawlik TM, Choti MA：Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 11：1057-1077, 2007

3）Abdalla EK, Adam R, Bilchik AJ, et al：Improving resectability of hepatic colorectal metastases：expert consensus statement. Ann Surg Oncol 13：1271-1280, 2006

4）大腸癌研究会（編）；大腸癌治療ガイドライン医師用2022年版．金原出版，2022

5）Benson AB, Venook AP, Al-Hawary MM, et al：Colon cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19：329-359, 2021

6）Van Cutsem E, Cervantes A, Adam R, et al：ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27：1386-1422, 2016

7）Kubota K, Makuuchi M, Kusaka K, et al：Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology 26：1176-1181, 1997

8）Johnson PJ, Berhane S, Kagebayashi C, et al：Assessment of liver function in patients with hepatocellular carcinoma：a new evidence-based approach-the ALBI grade. J Clin Oncol 33：550-558, 2015

9）Mise Y, Aloia TA, Brudvik KW, et al：Parenchymal-sparing hepatectomy in colorectal liver metastasis improves salvageability and survival. Ann Surg 263：146-152, 2016

10）Matsumura M, Mise Y, Saiura A, et al：Parenchymal-sparing hepatectomy does not increase intrahepatic recurrence in patients with advanced colorectal liver metastases. Ann Surg Oncol 23：3718-3726, 2016

11）Makuuchi M, Thai BL, Takayasu K, et al：Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma：a preliminary report. Surgery 107：521-527, 1990

12）Araki K, Shibuya K, Harimoto N, et al：A prospective study of sequential hepatic vein embolization after portal vein embolization in patients scheduled for right-sided major hepatectomy：results of feasibility and surgical strategy using functional liver assessment. J Hepatobiliary Pancreat Sci 30：91-101, 2023

13）Adam R, Laurent A, Azoulay D, et al：Two-stage hepatectomy：a planned strategy to treat irresectable liver tumors. Ann Surg 232：777-785, 2000

14）Schnitzbauer AA, Lang SA, Goessmann H, et al：Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 255：405-414, 2012

15）Sakamoto Y, Inagaki F, Omichi K, et al：Associating liver partial partition and transileocecal portal vein embolization for staged hepatectomy. Ann Surg 264：e21-e22, 2016

16）Beppu T, Sakamoto Y, Hasegawa K, et al：A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection：multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 19：72-84, 2012

17）Kishi Y, Zorzi D, Contreras CM, et al：Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 17：2870-2876, 2010

18）Kawaguchi Y, Kopetz S, Kwong L, et al：Genomic sequencing and insight into clinical heterogeneity and prognostic pathway genes in patients with metastatic colorectal cancer. J Am Coll Surg 233：272-284 e13, 2021

19）Nishioka Y, Kawaguchi Y, Kothari AN, et al：Prognostic and therapeutic implications of tumor biology, including gene alterations, in colorectal liver metastases. J Gastrointest Surg 25：1591-1600, 2021

20）Nordlinger B, Sorbye H, Glimelius B, et al：Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer（EORTC Intergroup trial 40983）：a randomised controlled trial. Lancet 371：1007-1016, 2008

21）Primrose J, Falk S, Finch-Jones M, et al：Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis：the New EPOC randomised controlled trial. Lancet Oncol 15：601-611, 2014

22）Matsumura M, Hasegawa K, Oba M, et al：A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases：EXPERT study. Langenbecks Arch Surg 407：1345-1356, 2022

23）Yoshizaki Y, Kawaguchi Y, Seki Y, et al：Posthepatectomy but not prehepatectomy chemotherapy was associated with a longer time to recurrence in patients with resectable colorectal liver metastases：inverse probability of treatment weighting analysis. J Hepatobiliary Pancreat Sci 30：1006-1014, 2023

24）Portier G, Elias D, Bouche O, et al：Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases：FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24：4976-4982, 2006

25）Mitry E, Fields AL, Bleiberg H, et al：Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer：a pooled analysis of two randomized trials. J Clin Oncol 26：4906-4911, 2008

26）Hasegawa K, Saiura A, Takayama T, et al：Adjuvant oral uracil-tegafur with leucovorin for colorectal cancer liver metastases：a randomized controlled trial. PLoS One 11：e0162400, 2016

27）Kanemitsu Y, Shimizu Y, Mizusawa J, et al：Hepatectomy followed by mFOLFOX6 versus hepatectomy alone for liver-only metastatic colorectal cancer（JCOG0603）：a phase Ⅱ or Ⅲ randomized controlled trial. J Clin Oncol 39：3789-3799, 2021

28）Ecker BL, Lee J, Saadat LV, et al：Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis：a retrospective study and meta-analysis. Lancet Oncol 23：1332-1342, 2022

29）Adam R, De Gramont A, Figueras J, et al：The oncosurgery approach to managing liver metastases from colorectal cancer：a multidisciplinary international consensus. Oncologist 17：1225-1239, 2012

30）Folprecht G, Gruenberger T, Bechstein WO, et al：Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab：the CELIM randomised phase 2 trial. Lancet Oncol 11：38-47, 2010

31）Vigano L, Procopio F, Cimino MM, et al：Is tumor detachment from vascular structures equivalent to R0 resection in surgery for colorectal liver metastases? An observational cohort. Ann Surg Oncol 23：1352-1360, 2016

32）Van Cutsem E, Köhne CH, Hitre E, et al：Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360：1408-1417, 2009

33）Kabbinavar FF, Hambleton J, Mass RD, et al：Combined analysis of efficacy：the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23：3706-3712, 2005

34）Venook AP, Niedzwiecki D, Lenz HJ, et al：Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer：a randomized clinical trial. JAMA 317：2392-2401, 2017

35）Shindoh J, Loyer EM, Kopetz S, et al：Optimal morphologic response to preoperative chemotherapy：an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 30：4566-4572, 2012

36）Nishioka Y, Shindoh J, Yoshioka R, et al：Radiological morphology of colorectal liver metastases after preoperative chemotherapy predicts tumor viability and postoperative outcomes. J Gastrointest Surg 19：1653-1661, 2015

37）Krieger PM, Tamandl D, Herberger B, et al：Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing. Ann Surg Oncol 18：1644-1650, 2011

38）Zhao J, van Mierlo KMC, Gomez-Ramirez J, et al：Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. Br J Surg 104：990-1002, 2017

39）Ribero D, Wang H, Donadon M, et al：Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110：2761-2767, 2007

40）Takamoto T, Hashimoto T, Sano K, et al：Recovery of liver function after the cessation of preoperative chemotherapy for colorectal liver metastasis. Ann Surg Oncol 17：2747-2755, 2010

41）Kanani A, Veen T, Soreide K：Neoadjuvant immunotherapy in primary and metastatic colorectal cancer. Br J Surg 108：1417-1425, 2021

42）Heinemann V, Stintzing S, Modest DP, et al：Early tumour shrinkage（ETS）and depth of response（DpR）in the treatment of patients with metastatic colorectal cancer（mCRC）. Eur J Cancer 51：1927-1936, 2015

43）Nakano H, Oussoultzoglou E, Rosso E, et al：Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247：118-124, 2008

44）Aloia T, Sebagh M, Plasse M, et al：Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24：4983-4990, 2006

45）Mise Y, Hasegawa K, Saiura A, et al：A multicenter phase 2 trial to evaluate the efficacy of mFOLFOX6＋cetuximab as induction chemotherapy to achieve R0 surgical resection for advanced colorectal liver metastases（NEXTO Trial）. Ann Surg Oncol 27：4188-4195, 2020

46）Watanabe G, Mise Y, Oba M, et al：A multicenter phase Ⅱ trial evaluating the efficacy of bevacizumab plus mFOLFOX6 for R0 surgical resection in advanced colorectal liver metastases harboring mutant-type KRAS：NEXTO-mt trial. HPB（Oxford） 24：1245-1251, 2022

47）Solheim JM, Dueland S, Line PD, et al：Transplantation for nonresectable colorectal liver metastases：long-term follow-up of the first prospective pilot study. Ann Surg 278：239-245, 2023

48）Makishima H, Yasuda S, Isozaki Y, et al：Single fraction carbon ion radiotherapy for colorectal cancer liver metastasis：A dose escalation study. Cancer Sci 110：303-309, 2019

49）Wright GP, Marsh JW, Varma MK, et al：Liver resection after selective internal radiation therapy with yttrium-90 is safe and feasible：a bi-institutional analysis. Ann Surg Oncol 24：906-913, 2017

50）Ruers T, Punt C, Van Coevorden F, et al：Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases：a randomized EORTC Intergroup phase Ⅱ study（EORTC 40004）. Ann Oncol 23：2619-2626, 2012